Back to User profile » Prof. Dr. Hikmat Abdel-Razeq
Papers published by Prof. Dr. Hikmat Abdel-Razeq:
Bridging Clinical Trials to Real-World Clinical Practice: TCHP Neoadjuvant Therapy Outcomes in HER2-Positive Breast Cancer
Sharaf B, Seif A, Bani Hani H, Alhasan M, Khader R, Al-Yag’oub M, Ghanem A, Bani Ata J, Ajlouni B, Jawarneh Q, Jaffal A, Tamimi F, Jehad S, Al-Abdallat H, Mahafdah O, Abdel-razeq H
Breast Cancer: Targets and Therapy 2026, 18:559555
Published Date: 9 April 2026
Enhancing Early Detection of Pancreatic Cancer in Genetically Predisposed Individuals: Integrating Advanced Imaging Modalities with Emerging Biomarkers and Liquid Biopsy
Abdel-Razeq R, Mansour A, Barbar M, Abu Shanap M, Sharaf B, Tamimi F, Mansour R, Muhanna A, Al-Othman Y, Hammad H, Shakhatreh M, Mahafdah S, Bani Hani H, Abdel-Razeq H
Biologics: Targets and Therapy 2025, 19:511-523
Published Date: 30 August 2025
Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
Al-Batsh T, Abdel-Razeq N, Al-Masri Y, El-Khatib O, Sharaf B, Tamimi F, Abdel-Razeq H
Biologics: Targets and Therapy 2025, 19:97-111
Published Date: 13 March 2025
Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights
Sharaf B, Tamimi F, Al-Abdallat H, Khater S, Salama O, Zayed A, El Khatib O, Qaddoumi A, Horani M, AL-Masri Y, Asha W, Altalla’ B, Bani Hani H, Abdel-Razeq H
Biologics: Targets and Therapy 2025, 19:59-71
Published Date: 5 March 2025
Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country
Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, El Khatib O, Edaily S, Abunasser M, Tamimi F, Al-Masri YN, Al-Batsh TMW, Zayed A, Ghatasheh T, Radaideh T
ImmunoTargets and Therapy 2024, 13:501-512
Published Date: 29 September 2024
Aggressiveness of Cancer Care at End of Life in Patients with Metastatic Breast Cancer in Jordan
Abunasser M, Abu-Fares H, Abdel-Razeq S, Shamieh O, Salama O, Ashouri K, Al Qudah A, Taqash A, Abu-Jaish H, Saadah SS, Abdel-Razeq H
Journal of Multidisciplinary Healthcare 2023, 16:2873-2881
Published Date: 26 September 2023
Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib
Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, Alhajahjeh A, Al-Lababidi S, Abdel-Razeq H
Breast Cancer: Targets and Therapy 2023, 15:541-548
Published Date: 28 July 2023
Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer
Abdel-Razeq H, Abujamous L, Al-Azzam K, Abu-Fares H, Bani Hani H, Alkyam M, Sharaf B, Elemian S, Tamimi F, Abuhijla F, Edaily S, Salama O, Abdulelah H, Daoud R, Abubaker M, Al-Atary A
Breast Cancer: Targets and Therapy 2023, 15:1-10
Published Date: 13 January 2023
Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer
Almasri H, Erjan A, Abudawaba H, Ashouri K, Mheid S, Alnsour A, Abdel-Razeq H
Breast Cancer: Targets and Therapy 2022, 14:363-373
Published Date: 29 October 2022
Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects
Abdel-Razeq H, Abu Rous F, Abuhijla F, Abdel-Razeq N, Edaily S
Clinical Interventions in Aging 2022, 17:1445-1460
Published Date: 28 September 2022
Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer
Marie L, Braik D, Abdel-Razeq N, Abu-Fares H, Al-Thunaibat A, Abdel-Razeq H
Cancer Management and Research 2022, 14:2519-2531
Published Date: 23 August 2022
Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
Edaily S, Abdel-Razeq H
OncoTargets and Therapy 2022, 15:815-826
Published Date: 27 July 2022
Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
Abdel-Razeq H, Sharaf B
Drug Design, Development and Therapy 2022, 16:727-735
Published Date: 16 March 2022
Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
Abdel-Razeq H, Sharaf B, AlMasri R, Abdel-Razeq R, Tamimi F, Khader O, Salama O, Abunasser M, Edaily S, Abdulelah H
Cancer Management and Research 2022, 14:1033-1041
Published Date: 8 March 2022
Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review
Sharaf B, AlMasri R, Abdel-Razeq N, Salama O, Hamad I, Abunasser M, Abdel-Razeq H
Clinical, Cosmetic and Investigational Dermatology 2022, 15:5-10
Published Date: 5 January 2022
Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
Abdel-Razeq H, Tamimi F, Abujamous L, Edaily S, Abunasser M, Bater R, Salama O
Cancer Management and Research 2021, 13:4597-4604
Published Date: 9 June 2021
Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country
Abdel-Razeq H, Almasri H, Abdel Rahman F, Abdulelah H, Abu Nasser M, Salam M, Al-Dairi A, Natour O, Rimawi D
Cancer Management and Research 2019, 11:9891-9897
Published Date: 22 November 2019
Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer
Abdel-Razeq H
Cancer Management and Research 2019, 11:4273-4282
Published Date: 8 May 2019
Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
Abdel-Razeq H, Saadeh SS, Abu-Nasser M, Abdulelah H, Marie L, Salam M, Al-Haj Ali B, Ibrahim M, Rimawi D
OncoTargets and Therapy 2018, 11:2091-2096
Published Date: 11 April 2018
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Abdel-Razeq H
Cancer Management and Research 2016, 8:127-128
Published Date: 20 October 2016
Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients
Abdel-Razeq H, Mansour A
Drug Design, Development and Therapy 2016, 10:2677-2679
Published Date: 24 August 2016
The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience
Mansour A, Ismael Y, Abunasser M, Hammode E, Turfa R, Abdel-Razeq H
Patient Preference and Adherence 2013, 7:1111-1116
Published Date: 23 October 2013
Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study
Abdel-Razeq H, Abbasi S, Saadi I, Jaber R , Abdulelah H
Drug Design, Development and Therapy 2013, 7:939-944
Published Date: 30 August 2013
Current neoadjuvant treatment options for HER2 positive breast cancer
Abdel-Razeq H, Marei L
Biologics: Targets and Therapy 2011, 5:87-94
Published Date: 9 August 2011
Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
Abdel-Razeq H, Ismael Y
Therapeutics and Clinical Risk Management 2011, 7:213-217
Published Date: 14 June 2011
Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome – a comprehensive cancer center experience
Hikmat N Abdel-Razeq, Asem H Mansour, Yousef M Ismael
Vascular Health and Risk Management 2011, 7:153-158
Published Date: 15 March 2011
Inferior vena cava filters in cancer patients: to filter or not to filter
Hikmat Abdel-Razeq, Asem Mansour, Yousef Ismael, et al
Therapeutics and Clinical Risk Management 2011, 7:99-102
Published Date: 10 March 2011